EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors

Yasuyuki Matsumoto iD, Tongzhong Ju

Cancers · 08.07.2023 · 15 (14) · 3536

DOI: 10.3390/cancers15143536 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 08.07.2023. Verfasst von Yasuyuki Matsumoto und 1 weiteren Autor:innen. Beteiligte Einrichtung: Office of Biotechnology Products, Center for Drug Evaluation and Research, The U.S. Food and Drug Administration, Silver Spring, MD 20993, USA. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 337 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glycosylation occurs at all major types of biomolecules, including proteins, lipids, and RNAs to form glycoproteins, glycolipids, and glycoRNAs in mammalian cells, respectively. The carbohydrate moiety, known as glycans on glycoproteins and glycolipids, is diverse in their compositions and structures. Normal cells have their unique array of glycans or glycome which play pivotal roles in many biological processes. The glycan structures in cancer cells, however, are often altered, some having unique structures which are termed as tumor-associated carbohydrate antigens (TACAs). TACAs as tumor biomarkers are glycan epitopes themselves, or glycoconjugates. Some of those TACAs serve as tumor glyco-biomarkers in clinical practice, while others are the immune therapeutic targets for treatment of cancers. A monoclonal antibody (mAb) to GD2, an intermediate of sialic-acid containing glycosphingolipids, is an example of FDA-approved immune therapy for neuroblastoma indication in young adults and many others. Strategies for targeting the aberrant glycans are currently under development, and some have proceeded to clinical trials. In this review, we summarize the currently established and most promising aberrant glycosylation as therapeutic targets for solid tumors.

Schlagwörter

Stichwörter der Autor:innen

CARTGD2Tn antigencancerglycansglyco-vaccineglycoproteinsglycosylationimmunotherapytumor-associated carbohydrate antigens (TACAs)

Autor:innen und Institutionen

  • Office of Biotechnology Products, Center for Drug Evaluation and Research, The U.S. Food and Drug Administration, Silver Spring, MD 20993, USA.

ORCID-Profile: Yasuyuki Matsumoto

Förderung

  • Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA)

Zitieren

APA

Matsumoto, Y., & Ju, T. (2023). Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors. Cancers, 15(14), 3536. https://doi.org/10.3390/cancers15143536

Vancouver

Matsumoto Y, Ju T. Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors. Cancers. 2023;15(14):3536. doi:10.3390/cancers15143536

BibTeX
@article{Matsumoto2023,
  author = {Matsumoto, Yasuyuki and Ju, Tongzhong},
  title = {Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {14},
  pages = {3536},
  doi = {10.3390/cancers15143536}
}
Kostenlos starten →